MANKIND · NSE
Mankind Pharma Limited
₹2,300.7
+0.03% (+₹0.7)
Prev. close
₹2,300
Volume
4,84,552
Delivery %
60.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Mankind Pharma Limited
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sheetal Arora
Headquarters
New Delhi
Employees
20,451
Website
mankindpharma.comExchange
View on NSE ↗Key stats
Market cap
₹95,029.28 Cr
P/E ratio (TTM)
46.5
Dividend yield
0.08%
EPS (TTM)
₹49.45
Beta (1Y · daily vs NIFTY 50)
0.70
Beta (5Y · monthly vs NIFTY 50)
0.63
Shares float
11.29 Cr
EPS · quarter ended Jun 2026
₹13.74
Upcoming earnings
29 Oct 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹8,749.43 Cr | ₹10,334.77 Cr | ₹12,207.44 Cr | ₹14,277.64 Cr | |
| EBITDA | — | — | ₹2,029.20 Cr | ₹2,815.93 Cr | ₹3,554.72 Cr | ₹3,846.45 Cr |
| ₹1,265.00 Cr | ₹1,433.00 Cr | ₹1,281.86 Cr | ₹1,912.90 Cr | ₹1,990.96 Cr | ₹1,912.93 Cr | |
| Diluted EPS | — | — | ₹32 | ₹47.68 | ₹49.19 | ₹46.28 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,360.00 Cr | ₹9,108.00 Cr | ₹9,686.00 Cr | ₹11,883.00 Cr | ₹27,652.00 Cr | ₹27,755.00 Cr | |
| — | — | ₹170.37 Cr | ₹207.17 Cr | ₹8,511.45 Cr | ₹6,311.54 Cr | |
| Stockholders' equity | ₹4,722.00 Cr | ₹6,155.00 Cr | ₹7,435.00 Cr | ₹9,363.00 Cr | ₹14,332.00 Cr | ₹16,300.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,137.00 Cr | ₹920.00 Cr | ₹1,813.00 Cr | ₹2,152.00 Cr | ₹2,413.00 Cr | ₹3,121.00 Cr | |
| Investing cash flow | — | — | ₹-1,054.13 Cr | ₹-2,081.69 Cr | ₹-12,682.95 Cr | ₹-196.42 Cr |
| — | — | ₹-739.73 Cr | ₹5.27 Cr | ₹10,290.13 Cr | ₹-2,952.69 Cr | |
| Capital expenditure | ₹-312.00 Cr | ₹-2,346.00 Cr | ₹-832.00 Cr | ₹-389.00 Cr | ₹-531.00 Cr | ₹-737.00 Cr |
| End cash position | — | — | ₹304.82 Cr | ₹382.01 Cr | ₹403.88 Cr | ₹391.69 Cr |
Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | May 23–Dec 23(4Q) | Mar 24 | Jun 24–Sep 24(2Q) | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 76.50% | 74.88% | 74.87% | 72.71% | 72.70% | 72.68% | 72.67% | 72.66% | 72.63% |
| Public | 23.50% | 25.12% | 25.13% | 27.29% | 27.30% | 27.32% | 27.33% | 27.34% | 27.37% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Mankind Pharma Limited | ₹92,758.89 Cr | ₹2,300 | 45.4 | 5.69 | 11.7% | 0.39 | +17.0% | -10.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
35 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Mankind Pharma Q2 FY27 Earnings Preview
Mankind Pharma's Q2 FY27 earnings date is not yet confirmed, though Indian regulations require results by November 14, 2026. The company's stock traded at Rs 2,250.00 on September 17, 2026, up 0.18%. Investors will compare Q2 FY27 results against Q1 FY27 net profit of Rs 574.00 crore and Q2 FY26 profit of Rs 520.00 crore.
Mankind Pharma to absorb Bharat Serums’ business through voluntary liquidation, bypassing NCLT merger route
Mankind Pharma will acquire Bharat Serums and Vaccines Limited (BSVL) through a voluntary liquidation process, bypassing the typical NCLT merger route. This method allows Mankind to absorb BSVL's business on a going-concern basis, subject to obtaining necessary approvals and licenses. The integration aims to improve operational efficiency and resource utilization across the combined entities.